New Active Substance Fee Outlined in Updated Health Canada Guidance

July 23, 2013
Fees for new drug reviews and applications in Canada rose by about 2 percent last month, according to updated guidance posted June 19 by Health Canada. The new fees took effect immediately. Sponsors submitting new active substances, clinical data, or chemistry and manufacturing data will also pay a review fee proportionate to the type and complexity of the examination.
International Pharmaceutical Regulatory Monitor